Gene · 688
Papers3,365
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
241 to 260 of 3,365
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Gallium complex K6 inhibits colorectal cancer by increasing ROS levels to induce DNA damage and enhance phosphatase and tensin homolog activity. | MedComm (2020) | 2024 | 39049965 | PubTator, text mining | PubMed |
| Bioinformatics and system biology approach to identify potential common pathogenesis for COVID-19 infection and sarcopenia. | Front Med (Lausanne) | 2024 | 38978778 | PubTator, text mining | PubMed |
| Lactate drives epithelial-mesenchymal transition in diabetic kidney disease via the H3K14la/KLF5 pathway. | Redox Biol | 2024 | 38925041 | PubTator, text mining | PubMed |
| The miRNA Contribution in Adipocyte Maturation. | Noncoding RNA | 2024 | 38921832 | PubTator, text mining | PubMed |
| KLF5 inhibition initiates epithelial-mesenchymal transition in non-transformed human squamous epithelial cells. | Biochim Biophys Acta Mol Cell Res | 2024 | 38909912 | PubTator, text mining | PubMed |
| A druggable cascade links methionine metabolism to epigenomic reprogramming in squamous cell carcinoma. | Proc Natl Acad Sci U S A | 2024 | 38900797 | PubTator, text mining | PubMed |
| PDP1 promotes KRAS mutant colorectal cancer progression by serving as a scaffold for BRAF and MEK1. | Cancer Lett | 2024 | 38849010 | PubTator, text mining | PubMed |
| Screening of drug targets for tuberculosis on the basis of transcription factor regulatory network and mRNA sequencing technology. | Front Mol Biosci | 2024 | 38841189 | PubTator, text mining | PubMed |
| PPIA dictates NRF2 stability to promote lung cancer progression. | Nat Commun | 2024 | 38830868 | PubTator, text mining | PubMed |
| Transcription factor EHF interacting with coactivator AJUBA aggravates malignancy and acts as a therapeutic target for gastroesophageal adenocarcinoma. | Acta Pharm Sin B | 2024 | 38799645 | PubTator, text mining | PubMed |
| Interruption of KLF5 acetylation promotes PTEN-deficient prostate cancer progression by reprogramming cancer-associated fibroblasts. | J Clin Invest | 2024 | 38781024 | PubTator, text mining | PubMed |
| Machine learning identifies activation of RUNX/AP-1 as drivers of mesenchymal and fibrotic regulatory programs in gastric cancer. | Genome Res | 2024 | 38777607 | PubTator, text mining | PubMed |
| linc-ADAIN, a human adipose lincRNA, regulates adipogenesis by modulating KLF5 and IL-8 mRNA stability. | Cell Rep | 2024 | 38753486 | PubTator, text mining | PubMed |
| Downregulation of KLF5 by EBER1 via the ERK signaling pathway in EBV-positive nasopharyngeal carcinoma cells: implications for latent EBV infection. | J Gen Virol | 2024 | 38747699 | PubTator, text mining | PubMed |
| Diagnostic and Prognostic Values of KLF5 and RUNX1 in Acute Kidney Injury in Septic Patients. | Appl Biochem Biotechnol | 2024 | 38727937 | PubTator, text mining | PubMed |
| Interstitial Fluid Shear Stress Induces the Synthetic Phenotype Switching of VSMCs to Release Pro-calcified Extracellular Vesicles via EGFR-MAPK-KLF5 Pathway. | Int J Biol Sci | 2024 | 38725857 | PubTator, text mining | PubMed |
A novel approach in biomedical engineering: The use of polyvinyl alcohol hydrogel encapsulating human umbilical cord mesenchymal stem cell-derived exosomes for enhanced osteogenic differentiation and angiogenesis in bone regeneration. | Int J Biol Macromol | 2024 | 38723803 | PubTator, text mining | PubMed |
| Ketogenesis attenuated KLF5 disrupts iron homeostasis via LIF to confer oxaliplatin vulnerability in colorectal cancer. | Biochim Biophys Acta Mol Basis Dis | 2024 | 38704001 | PubTator, text mining | PubMed |
| Curcumol reduces lower limb arteriosclerosis in rats by inhibiting human arterial smooth muscle cell activity. | Clin Exp Pharmacol Physiol | 2024 | 38684457 | PubTator, text mining | PubMed |
| KLF5 regulates actin remodeling to enhance the metastasis of nasopharyngeal carcinoma. | Oncogene | 2024 | 38649438 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/688/papers?page=13